BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brodszki N. Add-on or alone? Inhaled nebulized immunoglobulin reduces upper airway infections: 24 months of real-life experience. Immunotherapy 2020;12:389-94. [PMID: 32308072 DOI: 10.2217/imt-2019-0136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Kobayashi RH, Litzman J, Rizvi S, Kreuwel H, Hoeller S, Gupta S. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases. Immunotherapy 2022. [PMID: 34986666 DOI: 10.2217/imt-2021-0313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ventura-Carmenate Y, Alkaabi FM, Castillo-Aleman YM, Villegas-Valverde CA, Ahmed YM, Sanna P, Almarzooqi AA, Abdelrazik A, Torres-Zambrano GM, Wade-Mateo M, Quesada-Saliba D, Abdel Hadi L, Bencomo-Hernandez AA, Rivero-Jimenez RA. Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020. Transl Med Commun 2021;6:25. [PMID: 34746417 DOI: 10.1186/s41231-021-00101-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]